A single-center, cohort, observational study analysing impact of a pharmaceutical care program on the efficacy and safety of ibrutinib in patients with B cell malignancies
Latest Information Update: 11 Aug 2020
Price :
$35 *
At a glance
- Drugs Ibrutinib (Primary)
- Indications B-cell leukaemia; Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 11 Aug 2020 New trial record
- 01 Jul 2020 Primary endpoint has been met. (progression-free survival)
- 01 Jul 2020 Results published in the Annals of Hematology